Johan Selleslach

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Otto Soepenberg, Herlinde Dumez, Jaap Verweij et al. · Clinical Cancer Research · 2005 · 85 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Ecteinascidin‐743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

G. Huygh, Paul Clement, Herlinde Dumez et al. · Sarcoma · 2006 · 28 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I and Pharmacokinetic Study of Oral Irinotecan Given Once Daily for 5 Days Every 3 Weeks in Combination With Capecitabine in Patients With Solid Tumors

Otto Soepenberg, Herlinde Dumez, Jaap Verweij et al. · Journal of Clinical Oncology · 2005 · 28 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study

Herlinde Dumez, Marc Martens, Johan Selleslach et al. · Anti-Cancer Drugs · 2006 · 22 citations

Medicine, Oncology, Pharmacology +12

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

Patrick Schöffski, Ahmad Awada, Herlinde Dumez et al. · European Journal of Cancer Supplements · 2008 · 10 citations

Medicine, Oncology, Pharmacology +10